Bone Fractures and Prostate Cancer

Xofigo (Radium-223) - Cautionary Information

The European Medicines Agency (EMA) has recommended that the use of Xofigo (Radium-223) be restricted.  The restrictions, because of safety and efficacy concerns in men with castrate resistant prostate cancer (mCRPC), include that Xofigo can be used only after two other treatments have been taken; when other therapies cannot be used and not in combination with other 2nd line hormone therapies. 

Role and Precautions About to the Use of Bisphosphonate Drugs

Once a man with metastatic prostate cancer becomes castrate resistant (mCRPC) it is common to add a bisphosphonate like injectable zoledronic acid (Zometa) or denosumab (Xgeva) to his drug regimen.  Like all other drugs, bisphosphonates have unwanted side effects, some which can be mediated.